Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bradykinin B2 receptor antagonists: development and applications

J M Stewart1

  • 1Department of Biochemistry, University of Colorado Medical School, Denver 80262, USA.

Canadian Journal of Physiology and Pharmacology
|July 1, 1995
PubMed
Summary

Researchers have developed new antagonists for bradykinin B2 receptors, revolutionizing kinin research. These compounds show promise for biomedical applications and potential clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Transient immediate orthostatic hypotension' is preferable to 'initial' orthostatic hypotension.

Autonomic neuroscience : basic & clinical·2025
Same author

Combination Treatment with Antigen-Specific Dual-Sized Microparticle System Plus Anti-CD3 Immunotherapy Fails to Synergize to Improve Late-Stage Type 1 Diabetes Prevention in Nonobese Diabetic Mice.

ACS biomaterials science & engineering·2020
Same author

Engineering immunomodulatory biomaterials for type 1 diabetes.

Nature reviews. Materials·2020
Same author

First Report of Colletotrichum chlorophyti Infecting Soybean Seed in Arkansas, United States.

Plant disease·2019
Same author

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Investigational new drugs·2017
Same author

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Investigational new drugs·2017

Area of Science:

  • Pharmacology
  • Biochemistry
  • Physiology

Background:

  • Bradykinin exerts most physiological and pathophysiological effects through G-protein-coupled receptors, specifically B2 receptors.
  • The discovery of antagonists targeting B2 receptors has significantly advanced research within the kinin field.

Purpose of the Study:

  • To discuss the chemistry and development of B2 kinin receptor antagonists.
  • To present the uses of these antagonists in biomedical research.
  • To explore potential clinical applications of B2 receptor antagonists.

Main Methods:

  • Review of chemical synthesis and development strategies for B2 receptor antagonists.
  • Analysis of published research on the application of B2 antagonists in various biomedical models.
  • Evaluation of preclinical and clinical data regarding the therapeutic potential of B2 antagonists.

Main Results:

  • Significant progress has been made in the chemical design and synthesis of potent and selective B2 receptor antagonists.
  • B2 antagonists have proven invaluable as research tools, enabling detailed investigation of the kinin system's role in diverse physiological and pathological processes.
  • Several B2 antagonist candidates have demonstrated promising therapeutic potential in preclinical studies for conditions involving bradykinin.

Conclusions:

  • The development of B2 kinin receptor antagonists represents a major breakthrough, transforming the study of the kinin system.
  • These antagonists are crucial for both fundamental research and the development of novel therapeutic agents.
  • Further research into B2 antagonists holds significant promise for future clinical applications in managing bradykinin-mediated diseases.

Related Experiment Videos